Objective To investigate the expression of Rab35

TMPRSS4 and CIP2A proteins in endometrial carcinoma and its relationship with clinicopathological features and prognosis. Methods The clinical and follow-up data of 100 patients with endometrial carcinoma treated in a hospital in Fujian Province from January 2005 to January 2017 were collected. The expressions of Rab35

TMPRSS4 and CIP2A proteins in different tissues were compared. The relationship between Rab35

TMPRSS4

CIP2A protein and pathological parameters of patients with endometrial carcinoma was analyzed. The effects of Rab35

TMPRSS4 and CIP2A expression on the prognosis of patients with endometrial carcinoma

and the risk factors affecting the prognosis of patients with endometrial carcinoma were analyzed. Results The high expression rates of Rab35

TMPRSS4 and CIP2A protein in endometrial carcinoma tissues were significantly higher than those in adjacent normal tissues; and the difference was statistically significant.（χ

2

=62.947

122.120

42.762

all P

<

0.001）. The high expression rates of Rab35

CIP2A and TMPRSS4 in patients with endometrial carcinoma with myometrial invasion ≥1/2

tumor stage Ⅲ～Ⅳ

differentiation degree G1 and lymphatic metastasis were significantly higher than those with myometrial invasion depth

<

1/2

tumor stage Ⅰ～Ⅱ

differentiation degree G2

G3 and non-lymph node metastasis; and the difference was statistically significant（P

<

0.05）. The median survival time of patients with negative expression of Rab35

TMPRSS4 and CIP2A protein was longer than that of positive expression

and the difference was statistically significant（χ

2

=12.733

13.400

12.127

all P

<

0.001）. COX regression analysis showed that the depth of myometrial invasion ≥1/2

tumor stage Ⅲ～Ⅳ

tumor differentiation degree G1

lymphatic metastasis and high expression of Rab35

CIP2A and TMPRSS4 proteins were the risk factors for prognosis of patients with endometrial carcinoma（P

<

0.05）. Conclusion Rab35

TMPRSS4 and CIP2A proteins are highly expressed in endometrial carcinoma

and the expression of Rab35

TMPRSS4 and CIP2A proteins and the depth of myometrial invasion

tumor stage

differentiation and lymphatic metastasis will affect the prognosis of patients with endometrial carcinoma. Clinical monitoring of these indicators should be strengthened.